Hydrocodone addiction is an uncontrollable compulsion to use hydrocodone, a prescribed opioid pain reliever, despite harmful physical, psychological, and social consequences.
8.6 million people aged 12 or older, 3.0 percent of that population, misused prescription pain relievers in the past year.
SAMHSA, Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health
Signs and symptoms of hydrocodone addiction begin with increased tolerance and cravings, followed by a growing inability to control use, neglect of daily duties, emotional instability, social withdrawal, and persistent use despite harmful effects.
Causes of hydrocodone addiction include genetic vulnerability, environmental exposure, psychological conditions, medical overprescribing, previous substance abuse, rewarding drug effects, chronic pain, and stress-related coping challenges.
Hydrocodone addiction produces tolerance, physical dependence and withdrawal, degrades judgment and emotional regulation, narrows social life, and raises the risk of respiratory depression and fatal overdose. Sedation is one of the five adverse reactions the FDA label reports most frequently.
What is Hydrocodone Addiction?
Hydrocodone addiction is a chronic opioid use disorder characterized by compulsive hydrocodone seeking and use, impaired control over intake, continued use despite harm, and physiological dependence evidenced by tolerance and withdrawal.
Does Hydrocodone Have Codeine In It?
Hydrocodone products contain no codeine. Hydrocodone is a semisynthetic opioid that chemists synthesize from codeine or thebaine, two alkaloids in the resin of the opium poppy, so the finished molecule is a derivative rather than a mixture containing codeine.
Derivation describes where a molecule came from. Composition describes what is in the bottle. The National Institutes of Health LiverTox monograph calls hydrocodone "a semisynthetic derivative of codeine or thebaine, natural alkaloids derived from the resin of poppy seeds (Papaver somniferum)," and a semisynthetic derivative is a new compound with its own receptor behavior, not a blend of its starting material.
Ingredient lists settle the question product by product. Vicodin, Norco and Lortab are labeled as hydrocodone bitartrate and acetaminophen. Zohydro ER and Hysingla ER are labeled as hydrocodone bitartrate alone. Codeine appears in a separate family of medicines, among them acetaminophen and codeine phosphate tablets and several prescription cough preparations. No FDA-approved hydrocodone product carries codeine as an active ingredient.
Cross-tolerance is the real overlap between the two drugs. Both molecules occupy the mu-opioid receptor, so tolerance built on codeine carries over to hydrocodone and raises the dose it takes to feel anything. An allergy or adverse-reaction history with either drug belongs in front of a prescriber before the other one is dispensed.
Codeine vs Hydrocodone: What Is the Difference?
Codeine is a prodrug that depends on liver conversion to morphine for its pain relief, while hydrocodone is itself a full agonist at the mu-opioid receptor with approximately six times codeine's opiate activity, according to the NIH LiverTox monograph.
Metabolism separates the two drugs first. The FDA label for codeine records that 70 to 80 percent of a codeine dose is conjugated to codeine-6-glucuronide, 5 to 10 percent is O-demethylated to morphine, and about 10 percent becomes norcodeine. Analgesia rides on that 5-to-10-percent slice, and CYP2D6 is the enzyme that produces it, which is why CYP2D6 variation changes how much relief a given person gets from codeine.
Hydrocodone works on a different pathway. The label for hydrocodone bitartrate and acetaminophen states that "CYP3A4 mediated N-demethylation to norhydrocodone is the primary metabolic pathway of hydrocodone with a lower contribution from CYP2D6 mediated O-demethylation to hydromorphone." Hydrocodone relieves pain as itself, so a poor-metabolizer CYP2D6 phenotype does not switch its analgesia off the way it blunts codeine's.
Legal classification separates them second, and this is where outdated articles mislead. The Drug Enforcement Administration moved every hydrocodone combination product from Schedule III to Schedule II in a final rule effective October 6, 2014, so all hydrocodone now sits in Schedule II. Codeine remains split across schedules: codeine sulfate tablets are Schedule II, acetaminophen with codeine phosphate is Schedule III, and low-dose codeine cough preparations fall in Schedule V.
Pediatric restriction separates them third. The codeine sulfate label carries a boxed warning on death related to ultra-rapid metabolism of codeine to morphine, and it contraindicates codeine in all children younger than 12 years of age. Hydrocodone labels carry no equivalent metabolism-specific pediatric boxed warning, because hydrocodone does not depend on CYP2D6 activation to work.
How Long Does Hydrocodone Take To Work?
Hydrocodone reaches maximum serum concentration 1.3 hours after an oral dose, according to the pharmacokinetic data printed on the FDA label for hydrocodone bitartrate and acetaminophen tablets, and analgesia begins well before that peak as receptor occupancy rises.
The label reports the measurement with its error bars. Following a single 10 mg oral dose of hydrocodone given to five adult male subjects, mean peak concentration measured 23.6 plus or minus 5.2 nanograms per milliliter, maximum serum levels arrived at 1.3 plus or minus 0.3 hours, and the half-life came to 3.8 plus or minus 0.3 hours. Those figures are averages from a five-person study, and food, age, hepatic function and concurrent medicines all shift them.
Extended-release hydrocodone behaves nothing like the immediate-release form on this axis. Hysingla ER is a once-daily hydrocodone bitartrate tablet built so plasma concentration climbs across most of a day rather than peaking inside 90 minutes. Anyone comparing onset times needs to know which formulation is in front of them.
How Long Does Hydrocodone Last?
Immediate-release hydrocodone controls pain for 4 to 6 hours, which is the redosing interval the FDA label specifies, and its 3.8-hour elimination half-life sets that clock; extended-release hydrocodone is engineered to cover either 12 or 24 hours.
Two label numbers produce the duration answer. The medication guide for hydrocodone bitartrate and acetaminophen tablets instructs patients to take a prescribed dose "every four to six hours as needed for pain," and that interval is the manufacturer's own statement of how long one dose is expected to work. The 3.8-hour half-life explains why the window is that narrow: plasma concentration halves roughly every four hours, so the analgesic effect falls off on a similar arc.
Extended-release products stretch the window deliberately. Hysingla ER is administered orally once daily, every 24 hours. Zohydro ER is an extended-release hydrocodone capsule dosed every 12 hours. Neither formulation behaves like an immediate-release tablet, and crushing either one collapses a 12-hour or 24-hour release into a single bolus.
Duration of effect and detection window are separate measurements that diverge sharply. Effect fades when receptor occupancy drops below the analgesic threshold, while a laboratory assay detects hydrocodone and its metabolites long after any sensation has gone, so feeling nothing proves nothing about a test result.
Does Hydrocodone Make You Sleepy?
Hydrocodone causes sleepiness, and sedation sits on the FDA label's own list of the five most frequently reported adverse reactions for hydrocodone bitartrate and acetaminophen, alongside light-headedness, dizziness, nausea and vomiting, which makes drowsiness a direct pharmacological effect rather than an occasional surprise.
Mu-opioid receptors populate the brainstem and midbrain nuclei that regulate arousal, and hydrocodone binds them as a full agonist. The label states that hydrocodone "is full opioid agonist with relative selectivity for the mu-opioid (mu) receptor, although it can interact with other opioid receptors at higher doses." Occupying those receptors dampens ascending arousal signaling, which is the mechanism behind the drowsiness. The same receptor occupancy in the respiratory centers is what turns sedation from an inconvenience into a warning sign.
Trial data put a number on how common opioid somnolence is. During the open-label titration period of the Hysingla ER program, somnolence was reported in 5 percent of 905 patients.
Is Hydrocodone Sedation the Same as Sleep?
Hydrocodone sedation is not restorative sleep, because mu-opioid agonists suppress rapid eye movement sleep and slow wave sleep, the two stages that carry out physiological repair. Wang, D. and Teichtahl, H. (2007), "Opioids, sleep architecture and sleep-disordered breathing," Sleep Medicine Reviews 11(1):35-46, reports that induction and maintenance of opioid use reduce both REM sleep and slow wave sleep.
Breathing degrades during that sedation as well. Walker, J.M. and colleagues (2007), "Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing," Journal of Clinical Sleep Medicine 3(5):455-461, compared 60 patients taking chronic opioids against 60 patients matched for age, sex and body mass index who took none, and measured 12.8 central apneas per hour in the opioid group versus 2.1 per hour in the controls, at p less than .001. The authors concluded the relationship is dose-dependent. Sleeping more on hydrocodone and sleeping worse on hydrocodone happen at the same time.
What Makes Hydrocodone Drowsiness Dangerous?
Combining hydrocodone with a benzodiazepine, alcohol or any other central nervous system depressant carries an FDA boxed warning for profound sedation, respiratory depression, coma and death. That warning appears on every hydrocodone and acetaminophen label sold in the United States, and the label backs it with observational evidence that concomitant opioid and benzodiazepine use raises drug-related mortality above opioid use alone.
Escalating sedation is the visible edge of respiratory depression. Sedation progressing to stupor, skeletal muscle flaccidity, cold and clammy skin, constricted pupils and slowed or stopped breathing is a medical emergency that warrants a 911 call rather than an attempt to wake the person. Naloxone reverses opioid overdose by competing for opioid receptor sites, and its FDA indication covers known or suspected opioid overdose only. Naloxone does nothing for a benzodiazepine or stimulant overdose, because neither drug class acts at the opioid receptor naloxone occupies.
Driving is the everyday version of the same hazard. Hydrocodone impairs the mental and physical abilities needed to operate a vehicle or machinery, and the impairment is measurable whether or not the person feels sleepy.
What are the Signs and Symptoms of Hydrocodone Addiction?
Signs and symptoms of hydrocodone addiction include cravings for the drug, needing larger doses to achieve the same effect, loss of control over use, spending substantial time obtaining or using hydrocodone, and mood changes such as irritability or depression. For more details, see the table below.
Here are the common signs and symptoms of Hydrocodone addiction:
- Cravings for the drug
- Needing larger doses to achieve the desired effects
- Inability to control or reduce drug use
- Spending a significant amount of time obtaining, using, or recovering from the effects of hydrocodone
- Neglecting responsibilities at work, school, or home due to hydrocodone use
- Continued use of hydrocodone despite negative consequences
- Withdrawal symptoms when attempting to quit or reduce use
- Development of tolerance to hydrocodone's effects
- Social withdrawal and isolation
- Changes in mood or behavior, such as irritability, agitation, or depression
One symptom in isolation does not establish a diagnosis. A clinician diagnoses opioid use disorder against the American Psychiatric Association's DSM-5 criteria, which require at least 2 of 11 features inside a 12-month period, and grade severity as mild at 2 to 3 criteria, moderate at 4 to 5, and severe at 6 or more. Call Valley Spring Recovery Center at (855) 924-5320 to start an assessment.
What are the Causes of Hydrocodone Addiction?
The causes of hydrocodone addiction are biological factors, environmental and cultural influences, psychological factors, prescribing practices, a history of substance use, the drug’s rewarding effects, co-occurring mental health conditions, chronic pain management issues, and stress coping challenges.
Six risk factors recur across the research on opioid use disorder, and they compound rather than act alone.
- Inheriting genetic variation that alters opioid reward signaling. The National Institute on Drug Abuse attributes 40 to 60 percent of addiction vulnerability to genetics.
- Receiving a longer or higher-dose opioid prescription than the pain episode requires.
- Carrying an untreated psychiatric condition such as an anxiety disorder, major depressive disorder or PTSD, and using hydrocodone to blunt its symptoms.
- Living with chronic pain that keeps a person on an opioid for months rather than days.
- Having an earlier substance use disorder, which sensitizes the same mesolimbic reward circuitry hydrocodone acts on.
- Lacking non-drug means of regulating stress, so sedation becomes the coping strategy by default.
Risk compounds across those six, which is why two people on identical prescriptions diverge and why a clinical assessment examines psychiatric history and prior substance use rather than dose alone.
Why Do People Take Hydrocodone?
Hydrocodone treats pain severe enough to require an opioid analgesic when alternative treatments are inadequate, the indication its FDA label carries, and it suppresses cough in combination antitussive products. Post-surgical pain, injury and advanced cancer pain account for most prescriptions written.
Misuse follows different logic. Hydrocodone produces euphoria and sedation alongside analgesia, so people take extra doses to reach those effects, to quiet emotional distress, or to hold off withdrawal once dependence has formed. Physical dependence develops in people taking hydrocodone exactly as prescribed, which is why the FDA label defines dependence and addiction as separate states.
How Do People Take Hydrocodone?
Hydrocodone is swallowed as a tablet, an extended-release capsule or an oral solution, and combination products pair it with acetaminophen or ibuprofen. Crushing, snorting or dissolving and injecting a tablet defeats the formulation and delivers the whole dose at once, adding infection, vein damage, tissue damage and blood-borne disease to an already elevated overdose risk. Crushing an extended-release tablet destroys the mechanism that spreads one dose across the day.
What is the Difference Between Hydrocodone and OxyContin (Oxycodone)?
Hydrocodone and OxyContin differ in molecule, release profile and combination ingredient, not in legal class. OxyContin is an extended-release oxycodone tablet dosed every 12 hours. Hydrocodone reaches most patients as an immediate-release tablet combined with acetaminophen.
Both drugs sit in Schedule II of the Controlled Substances Act. The Drug Enforcement Administration ended the old split by moving hydrocodone combination products from Schedule III to Schedule II in a final rule effective October 6, 2014, and no hydrocodone product remains in Schedule III. Articles still describing hydrocodone as Schedule III predate that rule.
Acetaminophen is the difference that sends people to hospital for a reason unrelated to opioids. The hydrocodone and acetaminophen label instructs patients not to take more than 4,000 milligrams of acetaminophen per day and records that acetaminophen has caused acute liver failure resulting in liver transplant and death, with most cases occurring above that daily figure. Oxycodone as a single ingredient carries no such hepatic ceiling.
What Are The Effects of Hydrocodone Addiction?
Effects of Hydrocodone Addiction include:
- Euphoria and sedation alter pain perception.
- Drowsiness, dizziness, and sleepiness.
- Nausea, vomiting, and constipation.
- Increased tolerance and physical dependence.
- Mood changes such as depression and anxiety.
- Social withdrawal and neglect of responsibilities.
- Withdrawal symptoms on abrupt discontinuation, including muscle pain, insomnia, diarrhea and agitation.
- Respiratory depression, the mechanism through which opioid overdose kills.
- Acetaminophen liver injury in combination products, since most acetaminophen acute liver failure occurs above the 4,000 milligram daily ceiling the label sets.
- Impaired judgment and elevated accident risk, present whether or not the person feels sedated.
What are the Treatment Options for Hydrocodone Addiction?
Treatment for hydrocodone addiction combines medically supervised withdrawal, medication for opioid use disorder, structured outpatient therapy and long-term recovery support. Each component addresses a different part of the same problem, and the sequence below is the order clinicians follow for opioid addiction.
1. Medically Supervised Withdrawal
Opioid withdrawal management is a medical service delivered in a detox or inpatient setting rather than an outpatient one. Valley Spring Recovery Center does not provide detoxification. Valley Spring coordinates with licensed withdrawal-management providers and admits clients once withdrawal has been medically managed elsewhere. Opioid drug withdrawal rarely kills on its own; benzodiazepine and alcohol withdrawal do, through seizures, which is why medical supervision during withdrawal is a requirement rather than a preference. Withdrawal is also the point at which most unsupported attempts to stop collapse.
2. Medication for Opioid Use Disorder
Buprenorphine and naltrexone reduce opioid cravings and blunt withdrawal so that therapy becomes possible. Valley Spring Recovery Center prescribes Suboxone, buprenorphine, Naltrexone, Vivitrol, Brixadi and Topamax through its on-staff psychiatrist. Opioid dependence is among the most common reasons people enter Valley Spring, and buprenorphine and naltrexone carry that work. Methadone is dispensed only through federally certified opioid treatment programs, and Valley Spring does not hold that certification.
3. Behavioral Therapies
Cognitive behavioral therapy, contingency management and motivational interviewing change the thinking and the reinforcement patterns that sustain opioid use. Cognitive behavioral therapy targets the thoughts that precede use. Contingency management rewards verified abstinence. Motivational interviewing resolves ambivalence in people who have not yet committed to change.
4. Structured Outpatient Programming
Valley Spring Recovery Center runs three levels of outpatient care in Norwood, New Jersey: Restore at Partial Care, Activate at Intensive Outpatient, and Accelerate at Outpatient. Restore, licensed under New Jersey substance use license #200887, runs 9 AM to 3 PM Monday through Friday plus 9 AM to 12 PM Saturday. Activate runs 6 PM to 9 PM Monday through Friday. Accelerate runs 1 to 2 nights per week. Partial Care is delivered in person, and the two lower levels run in person or virtually by client preference.
5. Co-occurring Mental Health Care
Anxiety disorders, major depressive disorder and PTSD drive relapse when they go untreated alongside opioid use. Valley Spring Recovery Center holds a standalone New Jersey mental health license, #70420104, and tracks symptoms with the PHQ-9, GAD-7 and PCL-5 instead of self-report alone. Both conditions are treated together rather than in sequence.
6. Aftercare and Alumni Support
Recovery support after program completion consists of a written aftercare roadmap and continuing access to the Thrive alumni community, which runs monthly meetings, quarterly outings and peer mentorship. Every client who completes a Valley Spring Recovery Center program leaves with both.
Treatment matches the person rather than the drug. Call (855) 924-5320 to start an assessment.
What Are The Different Types and Brand Names Of Hydrocodone?
Hydrocodone has been sold under combination brand names including Vicodin, Norco and Lortab, and extended-release brand names including Zohydro ER and Hysingla ER. The combination brands pair hydrocodone bitartrate with acetaminophen. The extended-release brands contain hydrocodone bitartrate alone. Generic hydrocodone and acetaminophen tablets are identified by imprint rather than by brand name.
Vicodin
Vicodin is labeled as hydrocodone bitartrate and acetaminophen. Both ingredients carry independent risk: hydrocodone for respiratory depression and dependence, acetaminophen for liver injury.
Norco
Norco is labeled as hydrocodone bitartrate and acetaminophen in an immediate-release tablet. Norco, Vicodin and Lortab differ from one another in strength ratio, not in mechanism, onset or duration, which is why the same pharmacokinetic profile applies across all three.
Lortab
Lortab is labeled as hydrocodone bitartrate and acetaminophen and is supplied as tablets and as an oral solution. The boxed warning on the tablet product states that "Accidental ingestion of even one dose of Hydrocodone Bitartrate and Acetaminophen Tablets, especially by children, can result in a fatal overdose of hydrocodone," and an oral solution in a household with children raises that exposure.
Zohydro ER
Zohydro ER is an extended-release hydrocodone bitartrate capsule containing no acetaminophen, dosed every 12 hours for pain requiring around-the-clock opioid treatment. Hysingla ER is the once-daily tablet equivalent.
M367
M367 is the imprint on a generic immediate-release hydrocodone and acetaminophen tablet, not a brand. An imprint authenticates nothing: the DEA Laboratory found that six of every ten fentanyl-laced counterfeit prescription pills it analyzed in 2022 contained "a potentially lethal dose of fentanyl," and the agency's One Pill Can Kill alert names Vicodin among the medicines counterfeiters press to look nearly identical to the real product.